Topic: amyotrophic lateral sclerosis
PARP inhibitors prevent the misplacement of a specific protein that has been implicated in ALS, new research shows.
Blocking a pathway that causes healing cells to turn bad could offer a new way to treat neurological disorders.
Biogen has bolted on a couple of early-stage drug candidates for neuromuscular diseases via a $535 million deal with California startup AliveGen.
Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
BrainStorm will not provide its ALS treatment under right-to-try because it could not secure funding for all patients.
Flex Pharma is considering a sale or merger to keep afloat. In the meantime, it has scrapped two midstage trials and is cutting its workforce by 60%.
Aquinnah's new VP of research will head up its discovery efforts for treatments targeting neurodegenerative diseases.
Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.
Amgen joined with MP Healthcare Venture Management and Alexandria Venture Investments to put the latest tranche of funding into QurAlis.
MediciNova's ibudilast missed its primary endpoint of methamphetamine abstinence in a 12-week phase 2 trial.